Major shareholders: Ion Beam Applications, SA

NameEquities%Valuation
Sustainable Anchorage SARL
20.49 %
6,204,668 20.49 % 86 M €
Government of Belgium
4.7 %
1,423,271 4.7 % 20 M €
Belfius Insurance SA NV
3.927 %
1,189,196 3.927 % 17 M €
Paladin Asset Management Investmentaktiengesellschaft TGV
3.919 %
1,186,801 3.919 % 17 M €
Ion Beam Applications SA
3.807 %
1,152,754 3.807 % 16 M €
Van Lanschot Kempen Investment Management NV
2.891 %
875,388 2.891 % 12 M €
Société Régionale d'Investissement de Wallonie SA
2.363 %
715,491 2.363 % 10 M €
BNP Paribas Asset Management Belgium SA
1.824 %
552,432 1.824 % 8 M €
Investor Asset Management BV
1.459 %
441,748 1.459 % 6 M €
NS PARTNERS EUROPE SA
1.422 %
430,661 1.422 % 6 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Other23.05%
Institutional21.74%
Governments4.7%
Ion Beam Applications SA3.81%
L'Oréal SA0.37%
Unknown46.34%

Based on 1000 largest holdings

Geographical origin of shareholders

Belgium 43.01%
Germany 4.16%
Netherlands 2.89%
Luxembourg 1.49%
Norway 0.61%
Spain 0.57%
United Kingdom 0.53%
France 0.37%
Ireland 0.02%
Switzerland 0.01%

Based on 1000 largest holdings

Logo Ion Beam Applications, SA
Ion Beam Applications, SA (IBA) specializes in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. Net sales break down by family of products as follows: - diagnosis and therapeutic treatment equipment and systems (84.8%): proton therapy equipment (62.5% of net sales; No. 1 worldwide), and particle accelerators (36.5%) used in the production of radioisotopes (cyclotrons) and in the development of sterilization and ionization solutions (Rhodotron® and Dynamitron®); - equipment and solutions of dosimetry (15.2%; No. 1 worldwide): measurement and analysis tools of the radiation doses in medical imaging and radiation therapy. Net sales are distributed geographically as follows: the United States (31.7%) and other (68.3%).
Employees
1,943
Calendar
More about the company